Showing 5701-5710 of 6035 results for "".
- Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitishttps://modernod.com/news/nicox-initiates-phase-2-trial-of-ncx-4251-in-blepharitis/2476393/Nicox SA announced the initiation of a phase 2 clinical trial evaluating NCX 4251, its novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the first targeted topical treatm
- Nicox Signs Agreement for Zerviate in China for Up to €17 Million in Milestone Payments Plus Royaltieshttps://modernod.com/news/nicox-signs-agreement-for-zerviate-in-china-for-up-to-e17-million-in-milestone-payments-plus-royalties/2476381/Nicox SA and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of all
- Ivantis Announces 24-Month Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-24-month-results-of-landmark-prospective-randomized-comparative-migs-clinical-trial/2476379/Ivantis, developer of the Hydrus Microstent, announced the 24-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study were presented by Thomas Samuelson, MD, President of the American Society of Cataract and Refracti
- Glaukos: Study Confirms Long-Term Efficacy and Safety Profile of iStent in Combination with Cataract Surgeryhttps://modernod.com/news/study-confirms-long-term-efficacy-and-safety-profile-of-glaukos-istent-in-combination-with-cataract-surgery/2476375/Glaukos announced that results of an international glaucoma study published in the Journal of Cataract and Refractive Surgery showed use of iStent Trabecular Micro-Bypass Stent during cataract surgery delivered a 38% reduction in mean IOP to 14.7 mmHg after 5 years of follow-up. The
- Study Results Show NeurOptics’ NPi-200 Pupillometer Provides Early Warning of Neurological Damagehttps://modernod.com/news/study-results-show-neuroptics-npi-200-pupillometer-provides-early-warning-of-neurological-damage/2476358/A new study found that NeurOptics’ NPi-200 Pupillometer, which provides an automated assessment of the pupillary light reflex, may signal an early warning of potential delayed cerebral ischemia and enable preemptive escalation of care. The study was published in the Journal of Neurosurgery
- Roche/Genentech Initiate Two Large Phase 3 Studies in Wet AMD for Bispecific Molecule, Faricimabhttps://modernod.com/news/roche-genentech-initiate-two-large-phase-3-studies-in-wet-amd-for-bispecific-molecule-faricimab/2476355/Roche and Genentech have initiated two large global phase 3 clinical trials in wet age-related macular degeneration (AMD) investigating the bispecific molecule, faricimab. Faricimab is the first bispecific antibody designed specifically for the treatment of retinal eye diseases that simultaneousl
- 2019 Bressler Prize Awarded to Vladimir Kefalov, PhD, for Outstanding Accomplishments in Vision Science Researchhttps://modernod.com/news/2019-bressler-prize-awarded-to-vladimir-kefalov-phd-for-outstanding-accomplishments-in-vision-science-research/2476357/Lighthouse Guild announced that Vladimir Kefalov, PhD, has been awarded the 2019 Bressler Prize for his outstanding advances in vision science research. Dr. Kefalov is one of the leading retinal scientists in the world. His work has generated new insights into mecha
- Raindrop Near Vision Inlay Recalledhttps://modernod.com/news/fda-issues-recall-of-raindrop-near-vision-inlay/2476350/A Class I recall of the Raindrop near vision inlay has been issued due to an increased risk of corneal haze, according to the FDA. The owner of the Raindrop inlay, RVO 2.0, doing business as Optics Medical, issued the recall after an October warning letter from the FDA cited a post-approva
- New Laser Helps Doctors Image Full Eye in 3Dhttps://modernod.com/news/new-laser-helps-doctors-image-full-eye-in-3d/2476348/Scientists have developed a laser-based technique that can produce a full 3D image of all the layers of the retina, allowing doctors to better diagnose and treat eye diseases such as cataracts, diabetic retinopathy, and cancer, according to an Octlight news release. Researchers from the Te
- Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophyhttps://modernod.com/news/apellis-resumes-dosing-in-its-phase-3-program-for-patients-with-geographic-atrophy/2479589/Apellis Pharmaceuticals announced that it has resumed enrollment in its two phase 3 GA trials (DERBY & OAKS) with intravitreal APL-2 for the treatment of geographic atrophy (GA). In October 2018, Apellis